肝硬变与肝癌患者IL-2/IL-2R系统检测的意义

目的检测肝癌与肝硬变患者 IL-2/IL-2R 系统,比较其免疫功能并探讨其临床意义.方法对50例肝硬变、50例肝癌患者及30例正常对照进行检测,mIL-2R 表达采用免疫荧光法检测,IL-2活性及 sIL-2R 含量采用酶联免疫吸附法检测.结果肝癌患者 IL-2活性及 mIL-2R 表达低于肝硬变(P<0.01)及对照组(P<0.01),肝硬变患者 IL-2活性及 mIL-2R 表达亦较正常对照低(P<0.05);肝癌患者 sIL-2R 含量高于肝硬变(P<0.05)及对照组(P<0.01),肝硬变患者slL-2R含量亦高于正常对照(P<0.05).结论肝硬变与肝癌患者具有相似的免疫功能紊乱,且肝癌患者更为显著,免疫功能紊乱是肝硬变恶变的主要原因之一.     

晚期日本血吸虫病患者血清可溶性白细胞介素-2受体的研究

采用双抗体夹心ELISA法,检测47例晚期日本血吸虫病患者血清可溶性白细胞介素-2受体(sIL-2R),同时用间接免疫荧光法测定其外周血单个核细胞(PBMCs)膜IL-2受体(mIl-2R)的表达水平。结果表明晚血患者血清sIL-2R较正常人明显增高,而mIl-2R表达明显低下(P<0.01),其sIL-2R水平与mIl-2R表达呈负相关(r=-0`62,P<0.01).血清sIL-2R高低与COPT阳性与否无关,说明患者血清sIL-2R高低与病原体本身无直接关系,而与患者是否伴腹水有关,提示sIL-2R水平与疾病进展程度有关。观察患者血清sIL-2R的高低可作为疾病病程的监测指标。     

Changes of IL-6 and relevant cytokines in patients with hepatocellularcarcinoma and their clinical significance

AIM To study the changes of IL-6,IL-2, sIL-2R and TNF ir patients with hepatocellular carcinoma(HCC)and their clinical significance.METHODS IL-6, IL-2, sIL-2R and TNF were detected by avidin-biotin-system ELISA, double-sandwichELISA respectively in 60 patients with HCC and 36 patients with liver cirrhosis (LC) and 66 healthy persons.RESULTS The levels of IL-6, sIL-2R and TNF increased, but IL-2 level was lower in patients with HCCthan that in normal controls (NC) (t test, t=8.21, 4.71, 3.87, 2.13, P<0.01 or 0.05). IL-6 level in HCCwas 10 fold higher than NC, and also much higher than LC. IL-6 level was higher in later stage than that inearlier stage. There was a positive correlation between IL-6 and sIL-2R, TNF, while no positive correlationwas found between IL-2 and IL-6, sIL-2R in HCC.CONCLUSION The remarkably higher level of IL-6 is helpful for the early diagnosis of HCC.     

肝硬化与肝癌患者血清及腹水sIL—2R含量的研究

肝硬化失代偿期与原发性肝癌患者血清及腹水 sIL-2R 含量较正常人明显增高,腹水中 slL-2R 含量又较患者血清中的为高,显示 sIL-2R 能反映机体免疫功能状态,是肝硬化与肝癌患者临床免疫监测的可靠指标。     

Circulating insulin-like growth factor-binding protein 3 as prognostic biomarker in liver cirrhosis

AIM: To investigate the prognostic significance of insulin-like growth factor-binding protein 3(IGFBP-3) in patients with cirrhosis.METHODS: Prospective study that included two cohorts: outpatients with stable cirrhosis(n = 138) and patients hospitalized for acute decompensation(n = 189). Development of complications, mortality or liver transplantation was assessed by periodical phone calls and during outpatient visits. The cohort of stable cirrhosis also underwent clinical and laboratory evaluation yearly(2013 and 2014) in predefined study visits. In patients with stable cirrhosis, IGFBP-3 levels were measured at baseline(2012) and at second re-evaluation(2014). In hospitalized subjects, IGFBP-3 levels were measured in serum samples collected in the first and in the third day after admission and stored at-80 ℃. IGFBP-3 levels were measured by immunochemiluminescence.RESULTS: IGFBP-3 levels were lower in hospitalized patients as compared to outpatients(0.94 mcg/mL vs 1.69 mcg/m L, P 0.001) and increased after liver transplantation(3.81 mcg/m L vs 1.33 mcg/mL, P = 0.008). During the follow-up of the stable cohort, 17 patients died and 11 received liver transplantation. Bivariate analysis showed that death or transplant was associated with lower IGFBP-3 levels(1.44 mcg/mL vs 1.74 mcg/m L, P = 0.027). The Kaplan-Meier transplant-free survival probability was 88.6% in patients with IGFBP-3 ≥ 1.67 mcg/mL and 72.1% for those with IGFBP3 1.67 mcg/mL(P = 0.015). In the hospitalized cohort, 30-d mortality was 24.3% and was independently associated with creatinine, INR, SpO_2/FiO_2 ratio and IGFBP-3 levels in the logistic regression. The 90-d transplant-free survival probability was 80.4% in patients with IGFBP-3 ≥ 0.86 mcg/mL and 56.1% for those with IGFBP3 0.86 mcg/mL(P 0.001). CONCLUSION: Lower IGFBP-3 levels were associated with worse outcomes in patients with cirrhosis, and might represent a promising prognostic tool that can be incorporated in clinical practice.     

Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma

AIM: To evaluate the immunohistochemical localization of interleukin-6 (IL-6) and IL-6 receptor (IL-6R) on tumor tissue specimens from patients with hepatocellular carcinoma (HCC) and the serum levels of IL-6 and sIL-6R in a group of patients with HCC as well as liver cirrhosis (LC) in a group of patients with LC alone and in a control group. METHODS: Three groups of subjects were studied: groupⅠ(n=83) suffering from HCC and LC, groupⅡ(n=72) suffering from LC alone and groupⅢ(n=42) as healthy controls. All patients had hepatitis C virus infection. Serum IL-6 and IL-6R levels were determined using a commercially available ELISA kit. Immunohistochemistry was performed using the streptavidin-biotin complex and rabbit polyclonal antibodies against IL-6 and IL-6R. RESULTS: Immunohistochemistry analysis showed a medium to strong cytoplasmic and membrane reactivity for IL-6 and IL-6R respectively, in at least 40% of cases of HCC, whereas liver cirrhosis patients and controls were negative for IL-6 or showed a very mild and focal dot-like cytoplasmic reaction for IL-6R. Serum IL-6 levels in HCC group were significantly higher than those in LC and control groups (P<0.0001). There was no significant difference in sIL-6R concentrations among 3 groups. When the patients with HCC were divided into groups according to Okuda's classification, a significant serum increase of IL-6 and sIL-6R level was observed from stageⅠto stageⅢ(P<0.02,P<0.0005). When HCC and LC patients were divided into 3 classes of cirrhosis severity according to Child-Pugh, values in HCC patients were significantly higher than those in LC patients for each corresponding class (P<0.01). CONCLUSION: IL-6 serum levels in HCC patients are higher than those in LC patients and controls, suggesting an increased production of this cytokine by neoplastic cells. sIL-6R values are similar in all groups, increasing only in stageⅢHCC patients. These data suggest that they have a closer relationship with the neoplastic mass rather than with the residual functioning hepatic mass.     

Graves病患者外周血淋巴细胞的IL－1／IL－2R水平及临床意义

测定了３０例Ｇｒａｖｅｓ病（ＧＤ）患者外周血单个核细胞的白细胞介素－２（ＩＬ－２）活性、膜ＩＬ－２受体（ｍＩＬ－２Ｒ）和可溶性ＩＬ－２受体（ｓＩＬ－２Ｒ）水平。结果发现６Ｄ患者治疗前ＩＬ－２、ｍＩＬ－２Ｒ水平显著降低，ｓＩＬ－２Ｒ水平显著升高，且与同时测定的Ｔ＿３、Ｔ＿４、ＦＴ＿４Ｉ呈显著正相关；治疗后，随着甲状腺功能的逐渐改善而相应恢复至正常范围。这些结果提示：ＧＤ患者体内存在细胞因子的免疫调节紊乱，ＩＬ－２／ＩＬ－２Ｒ水平可以反映ＧＤ免疫动态，而高甲状腺素血症与免疫细胞的激活两者之间有一定关联。     

乙型肝炎肝硬化患者外周血dNLR、MLR和SII变化及其临床意义分析

目的 探讨乙型肝炎肝硬化患者外周血衍生中性粒细胞/淋巴细胞比值(dNLR)、单核细胞/淋巴细胞比值(MLR)和系统性免疫性炎症指数(SII)变化及其临床意义。方法 2019年1月～2021年12月我院收治的乙型肝炎肝硬化患者85例和慢性乙型肝炎(CHB)患者85例,采用ELISA法检测血清肿瘤坏死因子-α(TNF-α)、白介素-6(IL-6)和IL-17。常规检测血细胞计数。结果 乙型肝炎肝硬化患者血清TBIL和INR分别为(43.1±8.5)μmol/L和(1.3±0.6),显著高于【分别为(19.4±3.0)μmol/L和(1.1±0.2),P<0.05】,而血清ALT和ALB水平分别为(63.6±8.2)U/L和(30.8±4.6)g/L,显著低于CHB组【分别为(104.1±14.9)U/L和(39.0±8.1)g/L,P<0.05】;肝硬化患者血清TNF-α、IL-6和IL-17水平分别为(88.7±11.6)pg/mL、(95.6±12.5)pg/mL和(45.6±8.9)ng/mL,显著高于CHB组【分别为(68.2±9.3)pg/mL、(67.9±9.5)p...     

Serum levels of interleukin-10, interleukin-12 and soluble interleukin-2 receptor in chronic liver disease type C

BACKGROUND/AIMS: It is still unclear whether and how Th1/Th2 type cytokines are involved in the progression of chronic liver disease type C. We therefore examined serum levels of IL-10, IL-12 and sIL-2R (soluble IL-2 receptor) in association with clinical parameters in chronic liver disease type C, whereas IL-12 and sIL-2R represent Th1 cytokine and IL-10 does Th2 cytokine, respectively. METHODOLOGY: Serum levels of IL-10, IL-12 and sIL-2R were measured in 110 patients, including 36 with chronic hepatitis, 24 with liver cirrhosis and 50 with hepatocellular carcinoma in comparison with 19 normal individuals, by an enzyme-linked immunosorbent assay. In 9 chronic hepatitis patients, serum levels of these cytokines were measured before and after interferon therapy. In 28 with hepatocellular carcinoma, they were also measured before and after transcatheter arterial embolization. RESULTS: Serum levels of IL-10 in chronic hepatitis, liver cirrhosis and hepatocellular carcinoma were 3.9 +/- 1.8 pg/mL, 5.7 +/- 6.4 pg/mL and 5.6 +/- 8.9 pg/mL, respectively. IL-10 level was significantly correlated with level of y-globulin. Serum levels of IL-12 in chronic hepatitis, liver cirrhosis and hepatocellular carcinoma were 347.4 +/- 150.3 pg/mL, 365.2 +/- 130.7 pg/mL and 399.4 +/- 258.2 pg/mL. sIL-2R levels in chronic hepatitis, liver cirrhosis and hepatocellular carcinoma were 614.6 +/- 223.5 U/mL, 878.7 +/- 330.5 U/mL and 1037.9 +/- 412.0 U/mL. Serum levels of IL-12 and sIL-2R were significantly elevated on day 7 after interferon therapy compared to day 0 (p < 0.05 and p < 0.001, respectively), while no significant difference was seen in IL-10. Serum level of IL-10 was significantly elevated on day 3, and that of sIL-2R was elevated on day 3 and 7 after transcatheter arterial embolization, while that of IL-12 was decreased on day 3 and 7. CONCLUSIONS: The results of the present study suggest that Th1/Th2 type cytokines are changed in association with progression of chronic liver disease type C and in response to therapy.     

Increased soluble IL-2 receptor levels in HCV-infected haemophiliacs: a possible indicator of liver disease severity

SUMMARY. We have measured sIL-2R in 60 haemophiliacs and 20 male control subjects. Haemophiliacs were grouped according to their HIV/HCV antibody status. Group 1 ( n = 20) comprised HIV + ve/HCV + ve, group 2 ( n = 27) HIV - ve/HCV + ve and group 3 ( n = 13) HIV - ve/HCV - ve. Group 4 comprised the normal control subjects. We also examined, retrospectively, the relationship between the severity of chronic liver disease, assessed histologically, and sIL-2R levels in selected patients. There was no significant difference between sIL-2R levels of the group 1 and group 2 patients, and the levels for both were significantly greater than those of either the group 3 patients or the control subjects. sIL-2 levels were also higher in selected patients with cirrhosis than in those with chronic active hepatitis (CAH) or chronic persistent hepatitis (CPH). We conclude that in haemophiliacs, chronic HCV-related liver disease is associated with increased plasma levels of sIL-2R and that the degree of elevation may reflect the severity of the associated chronic liver disease.     

无肝素化连续性肾脏替代治疗肝硬化并发肝性脑病患者疗效研究*

目的 探讨无肝素化连续性肾脏替代疗法(CRRT)治疗肝硬化并肝性脑病(HE)患者的疗效以及血氨和细胞因子水平的变化。方法 2018年1月～2021年1月我院诊治的62例肝硬化并发HE患者,其中接受常规护肝和抗肝昏迷治疗31例(对照组),在此基础上接受无肝素化CRRT治疗31例(观察组)。采用ELISA法检测血清肿瘤坏死因子-α(TNF-α)、白介素-6(IL-6)和IL-10水平,采用谷氨酸脱氢酶法检测血氨水平。结果 观察组患者神志转清时间为(3.1±1.0)d,住院时间为(8.1±1.3)d,显著短于对照组【分别为(4.8±1.1)d和(12.5±1.5)d,P<0.01】,观察组患者病死率为6.5%,显著低于对照组的25.8%(P<0.05);治疗后,观察组血氨、TNF-α和IL-6水平分别为(69.3±10.5)mmol/L、(7.1±1.7)ng/L和(9.5±2.0)ng/L,显著低于对照组[分别为(94.8±8.1)mmol/L、(9.4±1.9)ng/L和(12.4±2.5)ng/L,P<0.01],而两组血清IL-10水平[(8.1±1.4)ng/L对(7.3±1.6)ng/L,P>0.01]比较,无显著性差异;观察组血清总胆红素水平为(41.2±8.6)μmol/L,显著低于对照组[(50.4±9.7)μmol/L,P<0.05],而两组血清白蛋白[(32.9±3.2)g/L对(32.4±2.8)g/L]和INR [(1.2±0.4)对(1.3±0.4)]相比,无显著性差异(P>0.05)。结论 采用无肝素化CRRT治疗肝硬化并发HE患者效果显著,可有效降低血氨和细胞因子水平,提高生存率,值得进一步观察。     

ITP患儿的白细胞介素2受体及NK细胞的研究

采用双抗夹心ELISA、APAAP桥联酶标法、MTT比色法检测了34例ITP患儿的血清可溶性白介素2受体（sIL-2R）外周血单个核细胞（PBMC）经PHA刺激后膜白介素2受体（mIL－2R）的表达、T淋巴细胞亚群以及自然杀伤（NK）细胞活性。结果：ITP患儿血清sIL－2R水平升高，mIL－2R的表达和NK活性显著降低；血清sIL－2R水平与NK活性、CD4 ／CD8 比值是负相关，与疾病严重程度和疗效密切相关。提示sIL－2R可作为监测病情、观察疗效的敏感指标；在纠正ITP的免疫调节紊乱中应充分考虑到细胞因子受体异常这个环节。     

慢性丙型肝炎患者血清microRNA-1273g-3p水平预测肝硬化价值分析*

目的 探讨慢性丙型肝炎(CHC)患者血清microRNA-1273g-3p水平预测发生肝硬化的价值。方法 2018年3月～2020年8月我院收治的CHC患者125例,采用实时荧光定量逆转录聚合酶链反应(qRT-PCR)法检测外周血microRNA-1273g-3p水平。应用Logistic回归分析CHC患者发生肝硬化的影响因素,绘制受试者工作特征曲线(ROC),计算曲线下面积,评估血清microRNA-1273g-3p水平预测CHC患者发生肝硬化的价值。结果 在本组125例CHC患者中,发现肝硬化42例(33.6%);肝硬化组BMI高、有输血史、血脂异常、未抗病毒治疗和血清microRNA-1273g-3p水平与CHC患者比,差异显著(P均<0.05),肝硬化组病程为(12.4±2.7)年,显著长于CHC组[(8.2±2.1)年,P＜0.01],肝硬化组血清microRNA-1273g-3p水平为(2.1±0.5),显著高于CHC组[(1.3±0.3),P＜0.01];经Logistic回归分析发现,以上因素均为影响CHC患者发生肝硬化的独立危险因素;经ROC分析显示,以血清microRNA-1273g-3p水平1.56为最佳截断点,其AUC值为0.844(95%CI:0.768～0.902),预测CHC患者发生肝硬化的灵敏度为78.6%(33/42,95%CI:73.1%～83.2%),特异度为86.8%(72/83,95%CI:82.5%～90.6%),准确度为90.4%(113/125,95%CI:73.1%～83.2%)。结论 检测血清microRNA-1273g-3p水平可能帮助预测CHC患者发生肝硬化,对及时诊治和管理具有一定的临床意义。     

T cell immune response is correlated with fibrosis and inflammatory activity in hepatitis B cirrhotics

AIM: To explore the relationship among interferon-γ(IFN-γ) activity, fibrogenesis, T cell immune responses and hepatic inflammatory activity. METHODS: Peripheral blood samples from a total of 43 hepatitis B cirrhotic patients (LC) and 19 healthy controls (NC) were collected to measure their serum levels of IFN-γ, interleukin-2 (IL-2), soluble interleukin-2 receptor (sIL-2R), interleukin-10 (IL-10) and three serological markers of fibrosis including hyaluronic acid (HA), procol-lagen typeⅢpeptide (PⅢP), and typeⅣcollagen were measured using a double antibody sandwich ELISA. Also, serum total bilirubin (TB) and alanine aminotransferase (ALT) were measured by routine measures. RESULTS: The concentrations of serological markers of fibrosis in patients with active cirrhosis (ALC) were significantly higher than those in stationary liver cirrhosis (SLC) or NC groups. The levels of serological markers in HBeAg-positive patients were significantly higher than those in HBeAg-negative patients. In SLC and ALC patients, a negative linear correlation was found between IFN-γlevels and the serological markers of fibrosis. IFN-γand IL-2 levels in the ALC group were significantly higher than those in the SLC and NC groups, but the statistical difference was not significant between the latter two. In contrast, IL-10 levels in the SLC group were significantly higher than that in the NC group, but no significant difference was found between SLC and ALC groups. The sIL-2R level was elevated gradually in all these groups, and the differences were significant. Positive linear correlations were seen between IFN-γactivity and ALT levels (r=0.339, P < 0.05), and IL-2 activity and TB levels (r=0.517, P < 0.05). SIL-2R expression was positively correlated with both ALT and TB levels (r=0.324, 0.455, P < 0.05), whereas there was no statistically significant correlation between IL-10 expression and serum ALT and TB levels (r = -0.102, -0.093, P > 0.05). Finally, there was a positive correlation between IFN-γand IL-2 levels. CONCLUSION: T cell immune responses are correlated with fibrosis and hepatic inflammatory activity and may play an important role in liver cirrhosis.     

白细胞介素2基因-330T/G和白细胞介素6基因-174G/C多态性与结核病易感性的Meta分析

目的 分析白细胞介素2(IL-2)基因-330T/G和IL-6基因-174G/C多态性与结核病易感性的关系。方法 在Medline、PubMed、EMBase、Web of Science、Elsevier Science Direct、万方数据库、中国知网(CNKI)和维普数据库中检索从1990年1月至2017年6月公开发表的关于IL-2和IL-6基因多态性与结核病易感性关系的中文和英文文献。初筛获得相关文献573篇,根据文献纳入和排除标准最终纳入文献12篇。应用Stata 12.0软件对各研究原始数据进行Meta分析。结果 IL-2基因-330T/G位点研究纳入文献共8篇,病例组971例,对照组1519名。Meta分析结果显示,欧洲人群中携带IL-2基因-330T等位基因者较携带-330G等位基因者患结核病风险低45%(T对G:OR=0.55;95%CI=0.31~0.98;P=0.042)。IL-6基因-174G/C位点纳入研究共9篇,病例组1445例,对照组1955名。Meta分析结果显示,美洲人群中携带IL-6基因-174G等位基因者患结核病风险是携带-174C等位基因者的1.65倍(G对C:OR=1.65;95%CI=1.28~2.13;P<0.01);亚洲人群中携带IL-6基因-174G等位基因者患结核病风险是携带-174C等位基因者的1.4倍(G对C:OR=1.40;95%CI=1.13~1.72;P=0.002)。结论 IL-2基因-330T/G位点等位基因T可能与欧洲人群结核病易感性风险降低相关;IL-6基因-174G/C位点等位基因G可能与美国人群和亚洲人群结核病易感性风险增加相关。     

MDS患者白细胞介素2受体表达研究

本实验以２８例ＭＤＳ（ＲＡ１８例、ＲＡＥＢ和ＲＡＥＢ－Ｔ１０例）和１０例ＡＮＬＬ为研究对象，采用ＡＰＡＡＰ和ＥＬＩＳＡ法检测患者外周血单个核细胞（ＰＨＡ刺激前后）的ＭＩＬ－２Ｒ和培养血清中ＳＴＬ－ＩＲ，结果表明：经ＰＨＡ刺激培养４８ｈ后，ＭＤＳ和ＡＮＬＬ患者Ｔａｃ抗原阳性率明显低于正常人（Ｐ＜０．０１）ＲＡＥＢ和ＲＡＥＢ－ｔ组Ｔａｃ＋率比ＲＡ低，与ＡＮＬＬ差异无显著性（Ｐ＞０．０５）；血清中ＳＴＬ－２Ｒ在ＭＤＳ各亚型中均高于正常对照组（Ｐ＜０．０５），其中以ＲＡＥＢ及ＲＡＥＢ－ｔ为著。认为ＭＤＳ患者免疫反应及监视能减弱；ＳＴＲ－２Ｒ与ｍＩＬ－２Ｒ无相关；ＩＬ－２Ｒ表达异常可能与造血抑制有关。     

Serum levels of soluble interleukin-2 receptors and effects of interferon-α for patients with chronic hepatitis C virus

To characterize the role of serum soluble interleukin-2 receptor (sIL-2R) in hepatitis C virus (HCV) infection, the level of sIL-2R was measured by ELISA in 117 subjects with chronic HCV infection and in 23 healthy controls. HCV RNA was detected by polymerase chain reaction in all subjects with HCV infection. Forty-seven patients with chronic hepatitis and 10 with liver cirrhosis were treated for six months with natural interferon-. The sIL-2R levels of 40 asymptomatic HCV carriers (632±340 units/ml), 47 patients with chronic hepatitis (547±204 units/ml), 10 with cirrhosis (679±239 units/ml), and 20 with hepatocellular carcinoma (1145±487 units/ml) were significantly higher than those of healthy controls (380±191 units/ml) (P<0.05, respectively). The levels of sIL-2R increased, as did the histological activity index scores (r=0.348,P<0.01). The level of sIL-2R rose after the initial administration of interferon in all 57 patients. In patients in whom HCV RNA was eliminated from the sera within a six-month follow-up after cessation of treatment, the level of sIL-2R reverted to basal values, but in patients in whom HCV RNA was not eliminated the value was significantly higher than that before treatment. These results suggest that monitoring serum sIL-2R in patients with chronic HCV infection treated with interferon may provide information concerning the possibility of the elimination of HCV RNA.     

Relationship between serum levels of soluble interleukin-2 receptor and various disease parameters in patients with squamous cell carcinoma of the esophagus.

BACKGROUND/AIMS: Soluble interleukin-2 receptor (sIL-2R) is a useful biomarker for the management of hematologic malignancies. We determined the significance of serum sIL-2R levels in patients with squamous cell carcinoma of the esophagus. METHODOLOGY: The correlation between serum sIL-2R levels and a variety of clinicopathologic factors in 51 patients with squamous cell carcinoma of the esophagus was evaluated. We also investigated the expression of IL-2R in the resected specimen using immunohistochemical staining. RESULTS: Expression of IL-2R was detected in primary esophageal carcinoma cells as well as infiltrating mononuclear cells. Serum sIL-2R levels in the 51 patients with esophageal cancer were significantly higher than those in the 18 healthy volunteers (p < 0.01). Multivariate analysis showed that pM, tumor size, and lymph node metastasis was significantly correlated with serum sIL-2R levels. Univariate analysis demonstrated that tumor size, pM, pTNM stage, and resectability were parameters which were significantly correlated with serum sIL-2R levels. There was no relationship between serum sIL-2 levels and tumor depth, lymph node metastasis, pT, histologic type, or curability. CONCLUSIONS: These results suggest that the serum sIL-2R levels may be an indicator of the extent of disease and resectability in patients with esophageal squamous cell carcinoma. Immunohistochemical staining suggests that esophageal cancer cells and infiltrating mononuclear cells may be the source of sIL-2R in the serum.     

未经治疗的原发性肝癌患者的免疫功能状态

对２８例未经任何治疗的中晚期原发性肝癌患者进行免疫功能的检测，并与正常比较，结果发现其ＩＬ－２系统中ＩＬ－２产生能力显著性降低，Ｔ淋巴细胞ｍＩＬ－２Ｒ表达非常显著性降低，而血清ｓＩＬ－２Ｒ水平非常显著性增加；外周血淋巴细胞绝对数及Ｔ淋巴细胞亚群分析表明前者明显降低，ＣＤ４细胞，ＣＤ４／ＣＤ８比值非常显著性降低，ＣＤ８细胞呈显著升高，相关性分析表明：ｓＩＬ－２Ｒ水平与ＣＤ４细胞，ＣＤ４／ＣＤ８比值呈     

FibroTouch诊断乙型肝炎病毒携带者肝纤维化价值研究*

目的 探讨使用FibroTouch无创检测诊断乙型肝炎病毒(HBV)携带者肝纤维化程度的效能。方法 2017年7月～2019年12月在深圳市龙岗中心医院感染病科住院的HBV携带者66例,所有患者均接受肝脏穿刺活检术。使用FibroTouch行肝脏硬度检测(LSM),常规计算基于4因子(FIB-4)指数,应用MedCalc软件绘制ROC曲线。结果 肝组织病理学检查提示,无显著肝纤维化(S₀～S₁)24例、进展期肝纤维化(S₂～S₃)27例和肝硬化(S₄)15例;无显著肝纤维化组LSM为(7.8±1.8) kPa,显著低于进展期肝纤维化组【(11.4±3.1)kPa,P＜0.01】或肝硬化组【(18.2±6.2)kPa,P＜0.01】患者,无显著肝纤维化组FBI-4指数为(1.0±0.5),与进展期肝纤维化组的(1.2±0.5)比,无显著性差异(P>0.05),但这两组FIB-4均显著低于肝硬化组[(2.0±1.0,P<0.01];LSM独立诊断S₂、S₃和S₄期肝纤维化的AUC分别为0.856(其敏感性为83.7%,特异性为52.6%)、0.938(其敏感性为92.3%,特异性为90.0%)和0.963(其敏感性为100.0%,特异性为90.2%),均显著高于FBI-4诊断的AUC(P<0.05),LSM联合FIB-4均不能提高诊断肝纤维化的效能(P>0.05)。结论 使用FibroTouch诊断乙型肝炎毒携带者肝纤维化有很大的临床应用价值,可无创检测,方便动态检测,定期复查。